Immunization against active ghrelin using virus-like particles for obesity treatment

Current Pharmaceutical Design

Volumn 19, Issue 36, 2013, Pages 6551-6558

  Andrade, Sara ^a   Pinho, Filipa ^a   Ribeiro, Andreia M ^a   Carreira, Marcos ^b   Casanueva, Felipe F ^b,c   Roy, Polly ^d   Monteiro, Mariana P ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Ghrelin; Obesity; Treatment; Vaccine; Virus like particles

Indexed keywords

ANTIBODY CONJUGATE; GHRELIN; NONSTRUCTURAL PROTEIN 1; PHOSPHATE BUFFERED SALINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BLUETONGUE ORBIVIRUS; BODY WEIGHT; CONTROLLED STUDY; DIET; ENERGY EXPENDITURE; FOOD INTAKE; GENE EXPRESSION; HYPOTHALAMUS; IMMUNIZATION; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ANIMALS; BODY WEIGHT; EATING; ENERGY METABOLISM; GHRELIN; HORMONES; IMMUNIZATION; MALE; MICE; MICE, INBRED C57BL; OBESITY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VACCINES, VIRUS-LIKE PARTICLE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84887880841     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990506     Document Type: Article

References (38)

1. WHO. DIET, NUTRITION AND THE PREVENTION OF CHRONIC DISEASES 2003. Available at http://www. who. int/mediacentre/news/releases/2003/pr20/en/. Acessed on 3 Jully 2009. 2003.
2. o311. Available at http://www. who. int/mediacentre/factsheets/fs311/en/print. html. Acessed 3 Jully 2009. 2006.
3. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health affairs 2009; 28: w822-31.
4. Rappange DR, Brouwer WB, Hoogenveen RT, Van Baal PH. Healthcare costs and obesity prevention: drug costs and other sector-specific consequences. PharmacoEconomics 2009; 27: 1031-44.
5. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10 Suppl 2: 97S-104S.
6. Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab 2008; 93: S81-8.
7. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obesity research 1998; 6 Suppl 2: 51S-209S.
8. Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity. Eur J Endocrinol 2008; 158: 135-45.
9. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30.
10. Monteiro MP, Ribeiro AH, Nunes AF, et al. Increase in ghrelin levels after weight loss in obese Zucker rats is prevented by gastric banding. Obes Surg 2007; 17: 1599-607.
11. Lu SC, Xu J, Chinookoswong N, et al. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol Pharmacol 2009; 75: 901-7.
12. Zakhari JS, Zorrilla EP, Zhou B, Mayorov AV, Janda KD. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Molecular pharmaceutics 2012; 9: 281-9.
13. Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007; 148: 5175-85.
14. Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Natl Acad Sci USA 2006; 103: 13226-31.
15. Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol 2007; 33: 176-89.
16. Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLPbased vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009; 49: 303-26.
17. Brown MJ. Therapeutic potential of vaccines in the management of hypertension. Drugs 2008; 68: 2557-60.
18. Hewat EA, Booth TF, Wade RH, Roy P. 3-D reconstruction of bluetongue virus tubules using cryoelectron microscopy. J Struct Biol 1992; 108: 35-48.
19. Ghosh MK, Borca MV, Roy P. Virus-derived tubular structure displaying foreign sequences on the surface elicit CD4+ Th cell and protective humoral responses. Virology 2002; 302: 383-92.
20. Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. Dig Dis Sci 2008; 53: 2293-9.
21. Puska P, Nishida, C., Porter, D., World Health Organization. Obesity and overweight. Available at http://www. who. int/dietphysicalactivity/publications/facts/obesity/e n/print. html. Acessed on 3 Jully 2009 2006.
22. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525-31.
23. De Vriese C, Delporte C. Ghrelin: a new peptide regulating growth hormone release and food intake. Int J Biochem Cell Biol 2008; 40: 1420-4.
24. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001; 25 Suppl 5: S63-7.
25. Chee MJ, Colmers WF. Y eat? Nutrition 2008; 24: 869-77.
26. Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab (Lond) 2007; 4: 18.
27. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J; 57: 359-72.
28. Williams G, Harrold JA, Cutler DJ. The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box. Proc Nutr Soc 2000; 59: 385-96.
29. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
30. Mayorov AV, Amara N, Chang JY, et al. Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. Proc Natl Acad Sci USA 2008; 105: 17487-92.
31. Lechner F, Jegerlehner A, Tissot AC, et al. Virus-like particles as a modular system for novel vaccines. Intervirology 2002; 45: 212-7.
32. Mikhailov M, Monastyrskaya K, Bakker T, Roy P. A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules. Virology 1996; 217: 323-31.
33. Dornonville de la Cour C, Lindqvist A, Egecioglu E, et al. Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice. Gut 2005; 54: 907-13.
34. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13.
35. Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004; 101: 8227-32.
36. Kellokoski E, Kummu O, Serpi R, et al. Ghrelin vaccination decreases plasma MCP-1 level in LDLR(-/-)-mice. Peptides 2009; 30: 2292-300.
37. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 1991; 88: 10931-5.
38. De Smet B, Depoortere I, et al. Energy homeostasis and gastric emptying in ghrelin knockout mice. J Pharmacol Exp Ther 2006; 316: 431-9.